


# RESEARCH REPORT



## SYNDROMIC MULTIPLEX PANELS MARKETS.

Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place and by Product. With Market Analysis and Executive Guides.

2023 to 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports, and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1 Market Guides .....24

    1.1 Situation Analysis ..... 25

    1.2 Guide for Executives and Marketing Staff ..... 28

    1.3 Guide for Investment Analysts and Management Consultants..... 30

2 Introduction and Market Definition .....32

    2.1 What are Syndromic Multiplex Tests? ..... 33

    2.2 Syndromic Testing – the quiet revolution in diagnostics ..... 34

        2.2.1 Syndromic Testing – more than Panels. .... 35

    2.3 Market Definition ..... 36

        2.3.1 Multiplex Market Size..... 36

        2.3.2 Currency. .... 36

        2.3.3 Years..... 37

    2.4 Methodology..... 38

        2.4.1 Methodology..... 38

        2.4.2 Sources..... 38

        2.4.3 Authors ..... 38

    2.5 Perspective: Healthcare and the IVD Industry ..... 40

        2.5.1 Global Healthcare Spending ..... 40

        2.5.2 Spending on Diagnostics ..... 41

        2.5.3 Important Role of Insurance for Diagnostics..... 43

3 The Infectious Diseases – Guide to the Pathogens.....44

    3.1 The Coronavirus..... 45

        3.1.1 Severe acute respiratory syndrome (SARS) ..... 47

- 3.1.2 Middle East respiratory syndrome (MERS) ..... 49
- 3.1.3 COVID-19. The SARS CoV 2 Virus..... 50
  - 3.1.3.1 Signs and symptoms ..... 51
  - 3.1.3.2 Transmission ..... 52
  - 3.1.3.3 Diagnosis ..... 53
  - 3.1.3.4 Prevention ..... 55
  - 3.1.3.5 Management..... 56
  - 3.1.3.6 Prognosis..... 57
  - 3.1.3.7 New Strains and Subsequent Mutations ..... 58
- 3.3 HIV - Human Immunodeficiency Virus (AIDS) ..... 59
  - 3.3.1 Virology ..... 59
    - 3.3.1.1 Classification ..... 59
    - 3.3.1.2 Structure and genome..... 60
    - 3.3.1.3 Tropism..... 62
    - 3.3.1.4 Replication cycle..... 65
    - 3.3.1.5 Genetic variability ..... 70
  - 3.3.2 Diagnosis ..... 72
  - 3.3.3 Testing..... 73
    - 3.3.3.1 Antibody tests ..... 73
    - 3.3.3.2 Point of Care Tests (POCT) ..... 76
    - 3.3.3.3 Antigen Tests ..... 79
    - 3.3.3.4 Nucleic acid-based tests (NAT) ..... 79
    - 3.3.3.5 Other tests used in HIV treatment..... 80
- 3.4 HBV – Hepatitis B..... 82
  - 3.4.1 Virology ..... 83
    - 3.4.1.1 Genome ..... 84

- 3.4.1.2 Pathogenesis..... 85
- 3.4.1.3 Hepatitis B virus replication ..... 85
- 3.4.1.4 Serotypes and genotypes..... 86
- 3.4.2 Mechanisms..... 86
- 3.4.3 Diagnosis ..... 87
- 3.4.4 Market Opportunity Analysis ..... 88
- 3.5 HCV – Hepatitis C..... 90
  - 3.5.1 Taxonomy..... 91
    - 3.5.1.1 Structure ..... 91
    - 3.5.1.2 Genome ..... 92
  - 3.5.2 Molecular biology ..... 93
  - 3.5.3 Replication..... 94
  - 3.5.4 Genotypes ..... 96
    - 3.5.4.1 Clinical importance ..... 96
  - 3.5.5 Market Opportunity Analysis ..... 97
- 3.6 2.4 HPV - Human papillomavirus..... 98
  - 3.6.1 Virology ..... 100
    - 3.6.1.1 E6/E7 proteins..... 100
    - 3.6.1.2 Role in cancer..... 100
    - 3.6.1.3 E2 research..... 101
    - 3.6.1.4 Latency period ..... 102
    - 3.6.1.5 Clearance ..... 102
  - 3.6.2 Diagnosis ..... 103
    - 3.6.2.1 Cervical testing ..... 103
    - 3.6.2.2 Oral testing ..... 105
    - 3.6.2.3 Testing men ..... 105

- 3.6.2.4 Other testing ..... 106
- 3.6.3 Market Opportunity Analysis ..... 107
- 3.7 Influenza..... 113
  - 3.7.1 Virology ..... 114
    - 3.7.1.1 Types of virus ..... 114
    - 3.7.1.2 Influenzavirus A ..... 114
    - 3.7.1.3 Influenzavirus B ..... 115
    - 3.7.1.4 Influenzavirus C ..... 115
    - 3.7.1.5 Structure, properties, and subtype nomenclature ..... 116
    - 3.7.1.6 Replication ..... 117
  - 3.7.2 Testing..... 119
    - 3.7.2.1 Advantages/Disadvantages of Molecular Assays..... 121
  - 3.7.3 Market Opportunity Analysis ..... 122
- 3.8 CTGC - Chlamydia/Gonorhea ..... 130
  - 3.8.1 Gonorrhea ..... 130
    - 3.8.1.1 Diagnosis ..... 131
    - 3.8.1.2 Screening ..... 131
  - 3.8.2 Chlamydia ..... 131
    - 3.8.2.1 Diagnosis ..... 132
    - 3.8.2.2 Screening ..... 133
  - 3.8.3 Testing..... 134
    - 3.8.3.1 Nucleic acid amplification tests (NAATs)..... 134
    - 3.8.3.2 Performance of NAAT Tests..... 142
  - 3.8.4 Market Opportunity Analysis ..... 143
- 3.9 Tuberculosis..... 145
  - 3.9.1 Mycobacteria..... 146

- 3.9.2 Diagnosis ..... 147
  - 3.9.2.1 Active tuberculosis ..... 147
  - 3.9.2.2 Latent tuberculosis..... 148
- 3.9.3 Epidemiology ..... 148
- 3.9.4 Molecular Diagnostic Tests ..... 150
- 3.9.5 Market Opportunity Analysis ..... 151
- 3.10 MRSA - Methicillin-resistant Staphylococcus aureus ..... 153
  - 3.10.1 Diagnosis ..... 153
  - 3.10.2 FDA Approved Molecular Tests ..... 154
  - 3.10.3 Market Opportunity Analysis ..... 155
- 3.11 VRE - Vancomycin-resistant Enterococcus ..... 156
  - 3.11.1 FDA Approved MDx Tests for VRE..... 157
  - 3.11.2 Market Opportunity Analysis ..... 158
- 4 Industry Overview.....159
  - 4.1 Players in a Dynamic Market..... 160
    - 4.1.1 Academic Research Lab ..... 161
    - 4.1.2 Diagnostic Test Developer..... 161
    - 4.1.3 Instrumentation Supplier ..... 162
    - 4.1.4 Chemical/Reagent Supplier..... 162
    - 4.1.5 Pathology Supplier ..... 162
    - 4.1.6 Independent Clinical Laboratory ..... 162
    - 4.1.7 Public National/regional Laboratory ..... 163
    - 4.1.8 Hospital Laboratory ..... 164
    - 4.1.9 Physicians Office Lab (POLs) ..... 164
    - 4.1.10 Audit Body ..... 165
    - 4.1.11 Certification Body..... 165



- 4.2 The Clinical Laboratory Market Segments ..... 167
  - 4.2.1 Traditional Market Segmentation..... 167
  - 4.2.2 Laboratory Focus and Segmentation..... 168
  - 4.2.3 Segmenting the Syndromic Testing Market..... 169
- 4.3 Industry Structure..... 171
  - 4.3.1 Hospital Testing Share ..... 171
  - 4.3.2 Economies of Scale..... 171
    - 4.3.2.1 Hospital vs. Central Lab..... 172
  - 4.3.3 Physician Office Lab's..... 173
  - 4.3.4 Physician's and POCT ..... 173
- 5 Market Trends ..... 175
  - 5.1 Factors Driving Growth ..... 176
    - 5.1.1 Speed of Diagnosis..... 176
    - 5.1.2 Effect of Syndromic Testing on Costs..... 177
    - 5.1.3 Point of Care Advantage..... 177
    - 5.1.4 Syndrome Testing, Accuracy and Diagnostic Risk..... 177
    - 5.1.5 Single Visits. .... 177
    - 5.1.6 Improvement in Outcomes. .... 178
    - 5.1.7 Impact of the Pandemic. .... 178
  - 5.2 Factors Limiting Growth ..... 179
    - 5.2.1 Lower Prices. .... 179
    - 5.2.2 Administration/reimbursement..... 180
    - 5.2.3 Infectious Disease is Declining But..... 182
    - 5.2.4 Wellness Hurts..... 182
    - 5.2.5 Economic Growth improves Living Standards. .... 182
    - 5.2.6 Impact of the Pandemic ..... 183

- 5.3 Instrumentation, Automation and Diagnostic Trends ..... 184
  - 5.3.1 Traditional Automation and Centralization..... 184
  - 5.3.2 The New Automation, Decentralization and Point of Care..... 184
  - 5.3.3 Instruments Key to Market Share ..... 186
  - 5.3.4 Bioinformatics Plays a Role ..... 186
  - 5.3.5 PCR Takes Command..... 187
  - 5.3.6 Next Generation Sequencing Fuels a Revolution..... 188
  - 5.3.7 NGS Impact on Pricing..... 189
  - 5.3.8 Whole Genome Sequencing, A Brave New World ..... 189
  - 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment ..... 190
  - 5.3.10 Comparing Syndrome and Targeted Testing ..... 191
  - 5.3.11 The Multiplex Paradigm Shift..... 193
  - 5.3.12 The Sepsis Testing Market – Bellwether for Syndromics..... 194
  - 5.3.13 The Single Visit and AntiMicrobial Resistance ..... 194
  - 5.3.14 Syndromics drives POCT adoption..... 195
- 6 Syndromic Testing Recent Developments ..... 196
  - 6.1 Recent Developments – Importance and How to Use This Section ..... 197
    - 6.1.1 Importance of These Developments ..... 197
    - 6.1.2 How to Use This Section..... 197
  - 6.2 BIOFIRE Announces New SPOTFIRE® System..... 197
  - 6.3 Startup Cambridge Nucleomics to Develop 'Nanobait' Tech for Multiplexed Testing 199
  - 6.4 Takara Bio Developing Multiplex Panels ..... 202
  - 6.5 Rover Diagnostics Developing Optical Multiplex PCR..... 203
  - 6.6 Nanopath Secures Funding to Develop POC Dx..... 204
  - 6.7 Genetic Signatures Wins Public Health Wales Contract..... 205
  - 6.8 Qiagen Looks to Long-Term Growth..... 206

6.9	LexaGene Gets Investment .....	210
6.10	Seegene Multiplex COVID-19/Flu/RSV Test Receives Approval .....	211
6.11	BforCure to Adapt Rapid PCR Platform for Cancer .....	212
6.12	Accelerated Growth for Decentralized Testing.....	212
6.13	QuantuMDx Developing Syndromic Panels for European Launch.....	220
6.14	Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel .....	225
6.15	QuantumDx Gets CE Mark for Rapid PoC PCR System.....	226
6.16	Bio-Rad Laboratories, Seegene Partner for MDx Development.....	227
6.17	Baebies to Expand Finder Platform.....	227
6.18	With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio .....	231
6.19	Binx Health Targeting Clinics, DTC & OTC With STI Tests .....	235
6.20	Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV .....	239
6.21	Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic .....	240
6.22	MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test .....	244
6.23	New Approach Involves Silicon-Based Test for Infectious Disease Screening.....	244
6.24	Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test .....	249
6.25	Qiagen sees NeuMoDx as Growth Vehicle .....	252
6.26	Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround.....	256
6.27	Roche, Speedx Partner to Expand Access to Antibiotic Resistance Tests .....	260
6.28	BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU.....	260
6.29	Infectious Disease Testing Firm Curative Acquires KorvaLabs .....	261
6.30	ChromaCode Raises Additional \$10M .....	262
6.31	COVID-19 Patients Need Syndromic Testing.....	262
6.32	GenMark Diagnostics – New Respiratory Panel due in June.....	264
6.33	Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark.....	265
6.34	Exact Diagnostics launches respiratory panel control.....	266

6.35	bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA .....	267
7	Profiles of Key Syndromic Testing Companies .....	269
7.1	Abacus Diagnostica .....	270
7.2	Abbott Laboratories.....	271
7.3	Accelerate Diagnostics.....	272
7.4	Ador Diagnostics.....	273
7.5	ADT Biotech .....	274
7.6	Akonni Biosystems .....	275
7.7	Alveo Technologies.....	276
7.8	Antelope Dx.....	277
7.9	Applied BioCode .....	278
7.10	Aureum Diagnostics.....	280
7.11	Aus Diagnostics .....	281
7.12	Baebies .....	282
7.13	Beckman Coulter Diagnostics.....	284
7.14	Becton, Dickinson and Company .....	285
7.15	Binx Health .....	287
7.16	Biocartis.....	288
7.17	BioFire Diagnostics (bioMérieux) .....	289
7.18	bioMérieux Diagnostics.....	291
7.19	Bio-Rad Laboratories, Inc.....	293
7.20	Bosch Healthcare Solutions GmbH.....	295
7.21	Cepheid (Danaher) .....	296
7.22	Credo Diagnostics Biomedical .....	298
7.23	Cue Health.....	299
7.24	Curetis N.V. / Curetis GmbH.....	301

7.25	Detect .....	302
7.26	Diagenode Diagnostics .....	303
7.27	Diasorin S.p.A. ....	304
7.28	Domus Diagnostics.....	306
7.29	Enzo Biochem .....	307
7.30	Eurofins Scientific .....	308
7.31	Fluxergy .....	310
7.32	Fusion Genomics. ....	311
7.33	Genetic Signatures.....	313
7.34	GenMark Dx (Roche) .....	314
7.35	Grip Molecular Technologies .....	316
7.36	Hibergene Diagnostics.....	317
7.37	Hologic .....	318
7.38	Immunexpress.....	320
7.39	Inflammatix .....	321
7.40	Invetech.....	322
7.41	Janssen Diagnostics .....	323
7.42	Karius .....	324
7.43	Lexagene .....	325
7.44	LightDeck Diagnostics .....	326
7.45	Lucira Health.....	327
7.46	Luminex Corp (DiaSorin) .....	328
7.47	Maxim Biomedical .....	330
7.48	Meridian Bioscience.....	331
7.49	Mesa Biotech (Thermo Fisher) .....	333
7.50	MicroGem.....	334

7.51 Millipore Sigma ..... 335

7.52 Minute Molecular ..... 336

7.53 Mobidiag (Hologic) ..... 337

7.54 Molbio Diagnostics ..... 338

7.55 Nanomix ..... 339

7.56 Novel Microdevices ..... 340

7.57 OnsiteGene ..... 341

7.58 Operon ..... 342

7.59 Oxford Nanopore Technologies ..... 343

7.60 Panagene ..... 344

7.61 Perkin Elmer ..... 345

7.62 Primerdesign (Novacyt) ..... 346

7.63 Prominex ..... 347

7.64 Proof Diagnostics ..... 348

7.65 Qiagen ..... 349

7.66 QuantuMDx ..... 351

7.67 QuidelOrtho ..... 352

7.68 Roche Molecular Diagnostics ..... 353

7.69 Saw Diagnostics ..... 355

7.70 Scope Fluidics ..... 356

7.71 Seegene ..... 357

7.72 Siemens Healthineers ..... 359

7.73 Sona Nanotech ..... 360

7.74 Speedx ..... 361

7.75 T2 Biosystems ..... 362

7.76 Talis Biomedical ..... 363

7.77 Thermo Fisher Scientific Inc..... 364

7.78 Vela Diagnostics..... 366

7.79 Veramarx ..... 367

7.80 Visby Medical ..... 368

7.81 XCR Diagnostics ..... 370

8 The Global Market for Syndromic Multiplex Diagnostics.....371

8.1 Global Market Overview by Country ..... 372

8.1.1 Table – Global Market by Country..... 372

8.1.2 Chart - Global Market by Country..... 373

8.2 Global Market by Syndrome - Overview ..... 374

8.2.1 Table – Global Market by Syndrome ..... 374

8.2.2 Chart – Global Market by Syndrome – Base/Final Year Comparison ..... 375

8.2.3 Chart – Global Market by Syndrome – Base Year ..... 376

8.2.4 Chart – Global Market by Syndrome – End Year..... 377

8.2.5 Chart – Global Market by Syndrome – Share by Year ..... 378

8.2.6 Chart – Global Market by Syndrome – Segments Growth..... 379

8.3 Global Market by Place - Overview ..... 380

8.3.1 Table – Global Market by Place..... 380

8.3.2 Chart – Global Market by Place – Base/Final Year Comparison ..... 381

8.3.3 Chart – Global Market by Place – Base Year..... 382

8.3.4 Chart – Global Market by Place – End Year ..... 383

8.3.5 Chart – Global Market by Place – Share by Year..... 384

8.3.6 Chart – Global Market by Place – Segments Growth ..... 385

8.4 Global Market by Product - Overview ..... 386

8.4.1 Table – Global Market by Product..... 386

8.4.2 Chart – Global Market by Product – Base/Final Year Comparison..... 387

- 8.4.3 Chart – Global Market by Product – Base Year ..... 388
- 8.4.4 Chart – Global Market by Product – End Year ..... 389
- 8.4.5 Chart – Global Market by Product – Share by Year ..... 390
- 8.4.6 Chart – Global Market by Product – Segments Growth ..... 391
- 9 Global Syndromic Multiplex Markets – By Syndrome .....392
  - 9.1 Respiratory ..... 393
    - 9.1.1 Table Respiratory – by Country ..... 393
    - 9.1.2 Chart - Respiratory Growth..... 394
  - 9.2 Gastrointestinal..... 395
    - 9.2.1 Table Gastrointestinal – by Country ..... 395
    - 9.2.2 Chart - Gastrointestinal Growth ..... 396
  - 9.3 Blood ..... 397
    - 9.3.1 Table Blood – by Country ..... 397
    - 9.3.2 Chart - Blood Growth..... 398
  - 9.4 Meningitis/Encephalitis ..... 399
    - 9.4.1 Table Meningitis/Encephalitis – by Country..... 399
    - 9.4.2 Chart - Meningitis/Encephalitis Growth ..... 400
  - 9.5 Sexually Transmitted Disease..... 401
    - 9.5.1 Table Sexually Transmitted Disease – by Country ..... 401
    - 9.5.2 Chart – Sexually Transmitted Disease Growth..... 402
  - 9.6 Other Syndrome ..... 403
    - 9.6.1 Table Other – by Country ..... 403
    - 9.6.2 Chart - Other Growth..... 404
- 10 Global MDx Infectious Disease Markets – by Place .....405
  - 10.1 Hospital Lab ..... 406
    - 10.1.1 Table Hospital Lab – by Country ..... 406



- 10.1.2 Chart - Hospital Lab Growth..... 407
- 10.2 Outpatient Lab..... 408
  - 10.2.1 Table Outpatient Lab – by Country ..... 408
  - 10.2.2 Chart - Outpatient Lab Growth ..... 409
- 10.3 Point of Care..... 410
  - 10.3.1 Table Point of Care – by Country..... 410
  - 10.3.2 Chart – Point of Care Growth..... 411
- 10.4 Other Place ..... 412
  - 10.4.1 Table Other – by Country ..... 412
  - 10.4.2 Chart - Other Place Growth ..... 413
- 11 Global MDx Infectious Disease Markets – by Product .....414
  - 11.1 Instruments..... 415
    - 11.1.1 Table Instruments – by Country ..... 415
    - 11.1.2 Chart - Instruments Growth..... 416
  - 11.2 Cartridges ..... 417
    - 11.2.1 Table Cartridges – by Country ..... 417
    - 11.2.2 Chart - Cartridges Growth..... 418
  - 11.3 Reagents..... 419
    - 11.3.1 Table Reagents – by Country ..... 419
    - 11.3.2 Chart - Reagents Growth ..... 420
  - 11.4 Other Product..... 421
    - 11.4.1 Table Other Product – by Country ..... 421
    - 11.4.2 Chart – Other Product Growth..... 422
- 12 Appendices.....423
  - 12.1 United States Medicare System: Clinical Laboratory Fees Schedule ..... 424
  - 12.2 The Most Used IVD Assays..... 526

12.3 The Highest Grossing Assays ..... 531

Table of Tables

Table 1 Characteristics of Coronavirus Pandemic Infections ..... 50

Table 2 COVID-19 Symptoms..... 52

Table 3 Classification of HIV Species..... 60

Table 4 HBV Tests - CMS Codes & Prices..... 90

Table 5 HCV Tests - CMS Codes & Prices ..... 97

Table 6 HPV Clearance Rates ..... 103

Table 7 HPV Tests - CMS Codes & Prices..... 108

Table 8 HPV Tests, Technology, Types ..... 109

Table 9 Types of Influenza Tests ..... 119

Table 10 Influenza Tests - CMS Codes & Prices..... 122

Table 11 FDA Cleared Molecular Assays for Influenza ..... 123

Table 12 FDA Cleared NAAT CTGC Tests ..... 135

Table 13 CTGC NAAT Target Sequences and Possible False Reactions ..... 140

Table 14 Influenza Tests - CMS Codes & Prices..... 144

Table 15 FDA Approved MDx Tests for Tuberculosis ..... 150

Table 16 Tuberculosis Tests - CMS Codes & Prices..... 151

Table 17 FDA Approved Tests for MRSA ..... 154

Table 18 MRSA Tests - CMS Codes & Prices ..... 156

Table 19 FDA Approved Tests for VRE ..... 157

Table 20 VRE Tests - CMS Codes & Prices ..... 158

Table 21 Market Players by Type ..... 161

Table 22 Clinical Laboratory Departments and Segments ..... 167

Table 23 Laboratory Management Focus – Different Approaches ..... 168

Table 24 Key Segmentation Variables Going Forward..... 169

Table 25 Possible Market Segments of Syndromic Multiplex Market ..... 169

Table 26 Five Factors Driving Growth ..... 176

Table 27 How SMT Improves Outcomes..... 178

Table 28 Four Factors Limiting Growth ..... 179

Table 29 Seven Key Diagnostic Laboratory Technology Trends ..... 184

Table 30 - Global Market by Region ..... 372

Table 31 Global Market by Syndrome ..... 374

Table 32 Global Market by Place..... 380

Table 33 Global Market by Product..... 386

Table 34 Respiratory by Country..... 393

Table 35 Gastrointestinal by Country ..... 395

Table 36 Blood by Country..... 397

Table 37 Meningitis/Encephalitis by Country..... 399

Table 38 Sexually Transmitted Disease by Country ..... 401

Table 39 Other by Country..... 403

Table 40 Hospital Lab by Country ..... 406

Table 41 Outpatient Lab by Country ..... 408

Table 42 Point of Care by Country..... 410

Table 43 Other by Country..... 412

Table 44 Instruments by Country ..... 415

Table 45 Cartridges by Country..... 417

Table 46 Reagents by Country ..... 419

Table 47 Other Product by Country ..... 421

Table 48 Clinical Lab Fee Schedule ..... 424

Table 49 The Most Common Assays..... 526

Table 50 Largest Revenue Assays..... 531

Table of Figures

Figure 1 Global Healthcare Spending ..... 41

Figure 2 The Lab Test Pie ..... 42

FIGURE 3 STRUCTURE OF CORONAVIRUSES ..... 46

Figure 4 HIV Virion ..... 61

Figure 5 Diagram of the HIV Replication Cycle ..... 65

Figure 6 The Structure of the HBV Virus..... 84

Figure 7 Hepatitis B Replication ..... 85

Figure 8 Structure of the HCV Virus..... 92

Figure 9 HCV Replication Cycle ..... 95

Figure 10 Structure of the Influenza Virion ..... 116

Figure 11 Influenza Replication..... 117

Figure 12 Scanning Electronmicrograph of Tuberculosis..... 146

Figure 13 The Road to Diagnostics ..... 160

Figure 14 Chart Death Rates and Infectious Disease Decline ..... 181

Figure 15 Centralized vs. Decentralized Laboratory Service ..... 185

Figure 16 A Highly Multiplexed Syndromic Testing Unit..... 185

Figure 17 The Real Cost to Sequence the Human Genome..... 188

Figure 18 The Codevelopment Process ..... 190

Figure 19 Comparing Syndromic and Targeted Testing..... 192

Figure 17 The Multiplex Paradigm Shift..... 193

Figure 21 Global Market Share Chart ..... 373

Figure 22 Global Market by Syndrome - Base vs. Final ..... 375

Figure 23 Global Market by Syndrome Base Year ..... 376

Figure 24 Global Market by Syndrome End Year ..... 377

Figure 25 Syndrome Share by Year ..... 378

Figure 26 Syndrome Segments Growth..... 379

Figure 27 Global Market by Place - Base vs. Final..... 381

Figure 28 Global Market by Place Base Year..... 382

Figure 29 Global Market by Place End Year ..... 383

Figure 30 Place Share by Year..... 384

Figure 31 Place Segments Growth ..... 385

Figure 32 Global Market by Product - Base vs. Final..... 387

Figure 33 Global Market by Product Base Year ..... 388

Figure 34 Global Market by Product End Year..... 389

Figure 35 Product Share by Year ..... 390

Figure 36 Product Segments Growth ..... 391

Figure 37 Respiratory Growth..... 394

Figure 38 Gastrointestinal Diagnostics Growth..... 396

Figure 39 Blood Growth..... 398

Figure 40 Meningitis/Encephalitis Growth..... 400

Figure 41 Sexually Transmitted Disease Growth ..... 402

Figure 42 Other Growth..... 404

Figure 43 Hospital Lab Growth..... 407

Figure 44 Outpatient Lab Growth ..... 409

Figure 45 Point of Care Growth ..... 411

Figure 46 Other Growth..... 413

Figure 47 Instruments Growth ..... 416

Figure 48 Cartridges Growth..... 418

Figure 49 Reagents Growth ..... 420

Figure 50 Other Product Growth ..... 422